Recovery ⏱ Half-life: Approximately 10-11 minutes. Despite short half-life, tissue-protective effects persist. Phase 2

ARA-290

ARA-290 (Cibinetide)

Updated March 15, 2026
Buy Now

Evidence at a Glance

Regulatory statusPhase 2
Cibinetide; non-erythropoietic EPO derivative; FDA Orphan Drug + Fast Track for sarcoidosis neuropathy; completed end-of-Phase-2, not approved.
Human evidenceLimited
Animal evidenceModerate

ARA-290 (cibinetide), a non-erythropoietic EPO-derived peptide, has completed small Phase 2 trials in sarcoidosis and diabetic neuropathy with encouraging nerve-repair signals but remains unapproved for any indication.

What the research does not support

  • Is not approved by the FDA or EMA; orphan-drug and fast-track designations are not approvals.
  • Does not stimulate red-blood-cell production like erythropoietin, despite being EPO-derived.
  • Human trials are small and disease-specific; benefits for general 'recovery' or tissue repair in healthy people are unproven.
Half-Life
Approximately 10-11 minutes. Despite short half-life, tissue-protective effects persist.
Mol. Weight
1257.34 g/mol

What is ARA-290?

ARA-290 (cibinetide) is a pioneering compound that separates the tissue-protective effects of erythropoietin from its blood cell-stimulating properties. It activates a distinct receptor complex that promotes repair without the risks associated with EPO use.

Research Applications

Neuropathy research, tissue protection, anti-inflammatory signaling, sarcoidosis, diabetic complications, and innate repair receptor biology.

Dosage Information (Research Use)

Clinical trial doses: 2-4 mg subcutaneously daily or three times weekly. Research use only.

Reconstitution & Handling

Standard BAC water reconstitution.

Half-Life & Pharmacokinetics

Approximately 10-11 minutes. Despite short half-life, tissue-protective effects persist.

Reported Observations in Literature

Well-tolerated in clinical trials. No erythropoietic effects. Mild injection site reactions reported.

Key Research References

  • Brines M, et al. “ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.” Mol Med. 2015

How ARA-290 Works

ARA-290 activates the Innate Repair Receptor (IRR), a heterodimer of EPO receptor and beta common receptor. Unlike erythropoietin, it does not stimulate erythropoiesis (red blood cell production). Instead, it triggers tissue-protective, anti-inflammatory, and anti-apoptotic signaling pathways.

Research Findings

Clinical trials for sarcoidosis-associated neuropathy and diabetic neuropathy have shown improvement in small nerve fiber density. Represents a new class of tissue-protective compounds.

Dosage & Administration

Clinical trial doses: 2-4 mg subcutaneously daily or three times weekly. Research use only.

Safety & Side Effects

Well-tolerated in clinical trials. No erythropoietic effects. Mild injection site reactions reported.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Sequence pGlu-Glu-Leu-Arg-Gln-Leu-Lys-Trp-Gln-Leu-Leu-NH2
Molecular Weight 1257.34 g/mol
Half-Life Approximately 10-11 minutes. Despite short half-life, tissue-protective effects persist.
Available Sizes 5mg
Storage Lyophilized: -20°C. Reconstituted: 2-8°C.

Key Research References

  • Brines M, et al. "ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes." Mol Med. 2015

Get ARA-290 from SourcePeptides

Third-party tested • Research-grade purity • Fast US shipping

Buy Now

Related Peptides

View all →
Cardiogen
Recovery
Short peptide bioregulator studied for cardiac tissue support, anti-fibrotic activity, and myocardial remodeling.
View Profile →
Cartalax
Recovery
Tripeptide bioregulator researched for cartilage tissue support and chondrocyte activity in joint degeneration models.
View Profile →
Vesugen
Recovery
Vascular-targeting tripeptide bioregulator researched for endothelial function and microcirculation support.
View Profile →